New tools for antigen delivery to the MHC class I pathway

Trends in Immunology

Volumn 25, Issue 2, 2004, Pages 92-97

  Morón, Gabriel ^a   Dadaglio, Gilles ^a   Leclerc, Claude ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CPG ISLAND; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SALMONELLA; TARGET CELL; VACCINATION;

EID: 0842303169     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.11.008     Document Type: Review

References (50)

1. Guermonprez P., et al. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:2002;621-667.
2. + T cell tolerance. J. Exp. Med. 196:2002;1627-1638.
3. Schulz M., et al. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;991-993.
4. den Boer A.T., et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 167:2001;2522-2528.
5. Marchand M., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
6. Rosenberg S.A., et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163:1999;1690-1695.
7. Amara R.R., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
8. Shiver J.W., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
9. Weiskirch L.M., Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. 158:1997;159-169.
10. Sirard J.C., et al. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes. J. Immunol. 159:1997;4435-4443.
11. Guermonprez P., et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature. 425:2003;397-402.
12. Houde M., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature. 425:2003;402-406.
13. Russmann H., et al. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science. 281:1998;565-568.
14. Rousset D., et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9:2003;885-887.
15. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
16. Klinman D.M., et al. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158:1997;3635-3639.
17. Stenmark H., et al. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. J. Cell Biol. 113:1991;1025-1032.
18. El Azami El Idrissi M., et al. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon. 40:2002;1661-1665.
19. Goletz T.J., et al. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12059-12064.
20. Lee R.S., et al. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 28:1998;2726-2737.
21. Carbonetti N.H., et al. Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Infect. Immun. 67:1999;602-607.
22. Noakes K.L., et al. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett. 453:1999;95-99.
23. Lippolis J.D., et al. Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways. Cell. Immunol. 203:2000;75-83.
24. De Haan L., et al. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway. Infect. Immun. 70:2002;3249-3258.
25. + T cell epitopes. J. Immunol. 156:1996;4697-4706.
26. Haicheur N., et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165:2000;3301-3308.
27. Carbonetti N.H., et al. Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector. AIDS Res. Hum. Retroviruses. 17:2001;819-827.
28. Guermonprez P., et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the α(M)β(2) integrin (CD11b/CD18). J. Exp. Med. 193:2001;1035-1044.
29. high dendritic cells. Eur. J. Immunol. 32:2002;3071-3081.
30. + T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3314-3319.
31. Fayolle C., et al. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J. Immunol. 162:1999;4157-4162.
32. Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2002;2385-2392.
33. + T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13:2001;437-441.
34. Melief C.J. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33:2003;2645-2654.
35. Nestle F.O., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
36. Albert M.L., et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1998;1359-1368.
37. Akiyama K., et al. Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells. J. Immunol. 170:2003;1641-1648.
38. Albert M.L., et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
39. Zitvogel L., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4:1998;594-600.
40. Regnault A., et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:1999;371-380.
41. Rodriguez A., et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:1999;362-368.
42. Boisgerault F., et al. Virus-like particles: a new family of delivery systems. Expert Rev. Vaccines. 1:2002;101-109.
43. + T cells and subsequently express CD8α and CD205 molecules. J. Exp. Med. 195:2002;1233-1245.
44. Bohm W., et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J. Immunol. 155:1995;3313-3321.
45. Greenstone H.L., et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1800-1805.
46. Sedlik C., et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;7503-7508.
47. Schirmbeck R., Reimann J. 'Empty' Ld molecules capture peptides from endocytosed hepatitis B surface antigen particles for major histocompatibility complex class I-restricted presentation. Eur. J. Immunol. 26:1996;2812-2822.
48. Moron V.G., et al. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol. 171:2003;2242-2250.
49. Rudolf M.P., et al. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166:2001;5917-5924.
50. Masignani V., et al. The value of vaccines. Vaccine. 21:(Suppl 2):2003;S110-S113.